A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas

NCT ID: NCT02868892

Last Updated: 2018-11-02

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-07-31
• Study Completion Date: 2017-07-31

Brief Summary

Patients with advanced or recurrent adenocarcinoma or adenosquamous cell carcinoma of the cervix will receive Pemetrexed.

Detailed Description

Patients will receive Pemetrexed 500 mg/m2 every three week.

On initiation of pemetrexed, on day one of first chemotherapy cycle, patients will begin taking folic acid at a dose of 350 to 600 mcg daily as well as receive an intramuscular injection of 1000 mcg of vitamin B12, with subsequent vitamin B12 injections given every 9 weeks while on study.

Conditions

Adenocarcinoma of the Cervix; Adenosquamous Cell Carcinoma of the Cervix

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Pemetrexed

Pemetrexed 500 mg/m2 will be administered on an outpatient basis on an every three week schedule. Pemetrexed will be administered as a 10 minutes intravenous (IV) infusion in (for 500-mg vial) 100 ml of saline via peripheral vein or central line on Day 1 of each 21 day cycle.

Group Type: EXPERIMENTAL

Pemetrexed

Intervention Type: DRUG

Pemetrexed 500 mg/m2

Interventions

Pemetrexed

Pemetrexed 500 mg/m2

Intervention Type: DRUG

Other Intervention Names

Alimta

Eligibility Criteria

Inclusion Criteria

1. Patients must have had advanced or recurrent adenocarcinoma or adenosquamous cell carcinoma of the cervix with documented disease progression

2. Patients must have had measurable disease defined as at least one lesion that could be accurately measured in at least one dimension, which must have been 20 mm when measured by conventional techniques including palpation, plain X-ray, computerized tomography (CT), and magnetic resonance imaging(MRI) or 10 mm when measured by spiral CT

3. 18 years of age or older

4. Eastern Cooperative Oncology Group (ECOG) performance status score < 2 and a life expectancy >3 months

5. Life expectancy ≥ 12 weeks

6. Participants must have measureable disease by RECIST criteria

7. Absolute neutrophil count > 1500 mm3, platelet count ≥ 100×109 L, hemoglobin ≥ 8.5 g/dL

8. Creatinine clearance ≥ 45 mL/min using the standard Cockcroft and Gault formula (below) or glomerular filtration rate (GFR) measured by Tc99m-diethylenetriaminepentacetate (DPTA) serum clearance method:

1. Males: [140 - Age in years] × Actual Body Weight (kg) 72 × Serum Creatinine (mg/dL)

2. Females: Estimated creatinine clearance for males × 0.85

9. Total bilirubin ≤ 2 mg/dL, aspartate transaminase (AST) and alanine transaminase (ALT) AST/ALT ≤ 5 times the upper limit of normal range

10. At least 21 days from administration of chemotherapy

11. No remaining grade 2 or higher toxicity from prior cancer therapies unless judged to be clinically insignificant by the Principal Investigator

12. At least four (4) weeks from prior major surgery

13. Willingness to provide permission to access archived tumor samples and additional blood samples for evaluation of Foundation One Analysis where available Enterprise wide.

14. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must be willing to use an acceptable contraceptive method (abstinence, oral contraceptive or double barrier method) for the duration of the study and for 30 days following the last dose of study drug, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial.

Exclusion Criteria

1. Uncontrolled cardiac disease, congestive heart failure, angina, arrhythmias or hypertension.

2. Myocardial infarction or unstable angina within 2 months of treatment.

3. Known human immunodeficiency virus (HIV) infection or chronic active Hepatitis B or C (patients are NOT required to be tested for the presence of such viruses prior to therapy on this protocol).

4. Active clinically serious infection > CTCAE (version 4.03) Grade 2.

5. Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.

6. Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 weeks of first dose of study drug.

7. Any other hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 weeks of first dose of study drug.

8. Serious non-healing wound, ulcer, or bone fracture.

9. Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.

10. Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements.

11. Concurrent severe illness such as active infection, or psychiatric illness/social situations that would limit safety and compliance with study requirements.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Western Regional Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

John Farley, MD

Role: PRINCIPAL_INVESTIGATOR

Western Regional Medical Center

Locations

Western Regional Medical Center, Inc.

Goodyear, Arizona, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

CWG2014034 Pemetrexed Cervica

Identifier Type: -

Identifier Source: org_study_id